Federal Register / Vol. 62, No. 161 / Wednesday, August 20, 1997 / Notices 44281

Shoushu Jiao, M.D., University of

Wisconsin: Based upon reports from the

University of Wisconsin as well as

information obtained by the Office of

Research Integrity (ORI) during its

oversight review, ORI found that Dr.

Jiao, former Research Associate,

Department of Pediatrics, University of

Wisconsin, engaged in scientific

misconduct by falsifying and creating

laboratory records while conducting

biomedical research. The data in these

records were reported in a National

Institute of Neurological Disorders and

Stroke (NINDS), National Institutes of

Health (NIH) grant application to

support a request for Public Health

Service (PHS) funding. Based on the

factual findings in the reports, the

following article has been retracted:

Jiao, S., Gurevich, V., & Wolff, J.A.

‘‘Long-term correction of rat model of

Parkinson’s disease by gene therapy.’’

Nature 362:450–453, 1993.

Dr. Jiao has entered into a Voluntary

Exclusion Agreement with ORI in which

he has voluntarily agreed:

(1) To exclude himself from serving in

any advisory capacity to PHS, including

but not limited to service on any PHS

advisory committee, board, and/or peer

review committee, or as a consultant for

a period of four (4) years, beginning on

August 8, 1997.

(2) To exclude himself from any

contracting or subcontracting with any

agency of the United States Government

and from eligibility for, or involvement

in, nonprocurement transactions (e.g.,

grants and cooperative agreements) of

the United States Government as

defined in 45 CFR part 76 (Debarment

Regulations) for a period of three (3)

years, beginning on August 8, 1997; and

(3) That any institution that submits

an application for PHS support for a

research project on which Dr. Jiao’s

participation is proposed, uses him in

any capacity on PHS supported

research, or submits a report of PHSfunded research in which he is involved

must concurrently submit a plan for

supervision of his duties to the funding

agency for approval for a period of one

(1) year following the three (3) year

exclusion. The supervisory plan must be

designed to ensure the scientific

integrity of Dr. Jiao’s research

contribution. The institution also must

submit a copy of the supervisory plan to

ORI.

FOR FURTHER INFORMATION CONTACT:

Acting Director, Division of Research

Investigations, Office of Research

Integrity, 5515 Security Lane, Suite 700,

Rockville, MD 20852, (301) 443–5330.

Chris B. Pascal,

Acting Director, Office of Research Integrity.

[FR Doc. 97–22082 Filed 8–19–97; 8:45 am]

BILLING CODE 4160–17–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Office of the Secretary

Findings of Scientific Misconduct

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

SUMMARY: Notice is hereby given that

the Office of Research Integrity (ORI)

has made a final finding of scientific

misconduct in the following case:

Jill A. London, Ph.D., University of

Connecticut Health Center: Based upon

a report from the University of

Connecticut Health Center as well as

information obtained by the Office of

Research Integrity (ORI) during its

oversight review, ORI found that Dr.

London, former Assistant Professor,

Department of Biostructure and

Function, School of Dental Medicine,

University of Connecticut Health

Center, engaged in scientific misconduct

by intentionally falsifying data in

conjunction with applying for and

reporting research supported by the

National Institute of Neurological

Disorders and Stroke (NINDS) and the

National Institute on Deafness and

Other Communication Disorders

(NIDCD), National Institutes of Health

(NIH).

Specifically, ORI found that Dr.

London’s grant applications and articles

contained numerous falsifications,

including:

(1) Figures 6, 7, and 8 in a paper

(London, J.A. & Cohen, L.B. ‘‘High time

resolution, multi-site optical

measurement of vertebrate

somatosensory cortex during

epileptiform discharges and vertebrate

gustatory cortex.’’ Optical Methods in

Neurobiology, pp. 61–78, 1988.)

prepared for the 11th Annual Meeting of

the European Neuroscience Association

(hereafter referred to as the European

Neuroscience paper) that cited support

by NINDS, NIH grants R01 NS08437 and

P01 NS16993;

(2) Figure 1A in a paper (London, J.A.,

‘‘Optical recording of activity in the

hamster gustatory cortex elicited by

electrical stimulation of the tongue.’’

Chemical Senses 15:137–143, 1990.)

that cited support by NINDS, NIH grants

R01 NS08437 and P01 NS16993; Figure

1A was found to be very similar or

identical to Figure 7 of the European

Neuroscience paper in #1 above;

(3) Figures 10 to 13 in grant

application 2 P50 DC00168–14,

‘‘Connecticut Chemosensory Clinical

Research Center,’’ submitted to NIDCD,

NIH on January 28, 1994; these figures

also appear as Figures 4 to 7 in grant

application 2 P50 DC00168–14A1,

submitted to NIDCD, NIH on September

28, 1994;

(4) Figures 2, 8, and 9 in grant

application 1 R01 DC01752–01,

‘‘Optical recording of hamster gustatory

cortex activity,’’ submitted to NIDCD,

NIH on January 29, 1992; these figures

were the same as Figures 11, 12, and 13,

respectively, in grant application 2 P50

DC00168–14 (see #3 above);

(5) Figures supplied for Figures 1 and

3 in grant application 1 F32 NS09601–

01, ‘‘Modular response patterns in

hamster gustatory cortex,’’ submitted to

NINDS, NIH on August 3, 1993; these

figures were the same as Figures 10 and

11, respectively, in grant application 2

P50 DC00168–14 (see #3 above);

(6) Figure 3 of a handout that Dr.

London provided during an NIH site

visit on April 25, 1994, conducted in

conjunction with the review of grant

application 2 P50 DC00168–14; the top

and bottom portions of Figure 3 of the

site visit handout were very similar or

identical to Figures 6 and 7,

respectively, of the European

Neuroscience paper (see #1 above), and

approximately 115 of the 125 traces

appearing in each of the figures showed

identities, with one or two ‘‘active’’

traces being identical;

(7) Figures 1, 2, and 3 in a paper

(London, J.A. & Wehby, R.G.

‘‘Classification of inhibitory responses

of hamster gustatory cortex.’’ Brain

Research 666:270–274, 1994.) that cited

support by NIDCD, NIH grants P50

DC00168 and T32 DC00025; and

(8) Nine figures included in a

manuscript (London, J.A. & Wehby, R.G.

‘‘Excitatory neural responses in the

hamster gustatory cortex.’’ Submitted to

Brain Research, 1996.) that cited

support by NIDCD, NIH grants P50

DC00168 and T32 DC00025. Dr. London

has accepted the ORI finding and has

entered into a Voluntary Exclusion

Agreement with ORI in which she has

voluntarily agreed, for a period of five

(5) years, beginning August 8, 1997:

(1) To exclude herself from any

contracting or subcontracting with any

agency of the United States Government

and from eligibility for, or involvement

in, nonprocurement transactions (e.g.,

grants and cooperative agreements) of

the United States Government as

defined in 45 C.F.R. Part 76 (Debarment

Regulations); and
44282 Federal Register / Vol. 62, No. 161 / Wednesday, August 20, 1997 / Notices

(2) To exclude herself from serving in

any advisory capacity to the Public

Health Service (PHS), including but not

limited to service on any PHS advisory

committee, board, and/or peer review

committee, or as a consultant. Dr.

London is required to submit a letter to

• Chemical Senses requesting a

retraction of the following article:

London, J.A. ‘‘Optical recording of

activity in the hamster gustatory cortex

elicited by electrical stimulation of the

tongue.’’ Chemical Senses 15:137–143,

1990;

• Brain Research requesting a

retraction of the following article:

London, J.A., & Wehby, R.G.

‘‘Classification of inhibitory responses

of the hamster gustatory cortex.’’ Brain

Research 666:270–274, 1994; and

• Optical Methods in Neurobiology

requesting a retraction of Section V,

Results—Hamster of the following

article: London, J.A., & Cohen, L.B.

‘‘High time resolution, multi-site optical

measurement of vertebrate

somatosensory cortex during

epileptiform discharges and vertebrate

gustatory cortex.’’ Optical Methods in

Neurobiology, pp. 61–78, 1988,

prepared for the 11th Annual Meeting of

the European Neuroscience Association.

FOR FURTHER INFORMATION CONTACT:

Acting Director, Division of Research

Investigations, Office of Research

Integrity, 5515 Security Lane, Suite 700,

Rockville, MD 20852, (301) 443–5330.

Chris B. Pascal,

Acting Director, Office of Research Integrity.

[FR Doc. 97–22081 Filed 8–19–97; 8:45 am]

BILLING CODE 4160–17–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Food and Drug Administration

[Docket No. 97F–0301]

Ube Industries (America), Inc.; Filing of

Food Additive Petition; Correction

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice; correction.

SUMMARY: The Food and Drug

Administration (FDA) is correcting a

notice that appeared in the Federal

Register of July 21, 1997 (62 FR 39003).

The document announced that Ube

Industries (America), Inc., filed a

petition proposing that the food additive

regulations be amended to change the

melting point range specifications for

Nylon 6/66 resins intended for use in

contact with food. The document

published with an incorrect docket

number. This document corrects that

error.

FOR FURTHER INFORMATION CONTACT: Vir

D. Anand, Center for Food Safety and

Applied Nutrition (HFS–215), Food and

Drug Administration, 200 C St. SW.,

Washington, DC 20204, 202–418–3081.

In FR Doc. 97–19127, appearing on

page 39003 in the Federal Register of

Monday, July 21, 1997, the following

correction is made:

1. On page 39003, in the first column,

Docket No. ‘‘97N–0301’’ is corrected to

read ‘‘97F–0301’’.

Dated: August 13, 1997.

William K. Hubbard,

Associate Commissioner for Policy

Coordination.

[FR Doc. 97–22091 Filed 8–19–97; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Food and Drug Administration

Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

This notice announces a forthcoming

meeting of a public advisory committee

of the Food and Drug Administration

(FDA). The meeting will be open to the

public.

Name of Committee: Anesthetic and

Life Support Drugs Advisory

Committee.

General Function of the Committee:

To provide advice and

recommendations to the agency on FDA

regulatory issues.

Date and Time: The meeting will be

held on September 17, 1997, 8 a.m. to

5 p.m.

Location: Gaithersburg Hilton, Grand

Ballroom, 620 Perry Pkwy.,

Gaithersburg, MD.

Contact Person: Karen M. TempletonSomers or Robin M. Spencer, Center for

Drug Evaluation and Research (HFD–

21), Food and Drug Administration,

5600 Fishers Lane, Rockville, MD

20857, 301–443–5455, or FDA Advisory

Committee Information Line, 1–800–

741–8138 (301–443–0572 in the

Washington, DC area), code 12529.

Please call the Information Line for upto-date information on this meeting.

Agenda: The committee will hear

presentations and discuss data

submitted regarding new drug

application (NDA) 20–747, ActiqTM (oral

transmucosal fentanyl citrate, drug

matrix on a handle), Anesta Corp., for

the management of chronic pain,

particularly breakthrough pain, in

patients who are already receiving and

are tolerant to opioid therapy.

Procedure: Interested persons may

present data, information, or views,

orally or in writing, on issues pending

before the committee. Written

submissions may be made to the contact

person by September 4, 1997. Oral

presentations from the public will be

scheduled between approximately 8

a.m. and 8:30 a.m. and 3 p.m. and 3:30

p.m. Time allotted for each presentation

may be limited. Those desiring to make

formal oral presentations should notify

the contact person before September 4,

1997, and submit a brief statement of

the general nature of the evidence or

arguments they wish to present, the

names and addresses of proposed

participants, and an indication of the

approximate time requested to make

their presentation.

Notice of this meeting is given under

the Federal Advisory Committee Act (5

U.S.C. app. 2).

Dated: August 14, 1997.

Michael A. Friedman,

Deputy Commissioner for Operations.

[FR Doc. 97–22090 Filed 8–19–97; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Food and Drug Administration

Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

This notice announces a forthcoming

meeting of a public advisory committee

of the Food and Drug Administration

(FDA). The meeting will be open to the

public.

Name of Committee: Blood Products

Advisory Committee.

General Function of the Committee:

To provide advice and

recommendations to the agency on FDA

regulatory issues.

Date and Time: The meeting will be

held on September 18, 1997, 8 a.m. to

5:30 p.m., and September 19, 1997, 8

a.m. to 4 p.m.

Location: Quality Suites Hotel,

Potomac Rooms I, II, and III, Three

Research Ct. (off Shady Grove Rd.),

Rockville, MD.

Contact Person: Linda A. Smallwood,

Center for Biologics Evaluation and

Research (HFM–350), Food and Drug

Administration, 1401 Rockville Pike,

Rockville, MD 20852, 301–827–3514, or

FDA Advisory Committee Information